HOME PRIVACY POLICY QUALITY POLICY COVID-19 PENS therapy PROBES INDICATIONS PATIENT FAQ's CLINICAL PRESS CONGRESSES CONTACT DISTRIBUTORS

PENS therapy now MEDSAFE approved for New Zealand

FEATURED POSTS

PERCUTANEOUS ELECTRICAL NERVE STIMULATION (PENS) THERAPY FOR REFRACTORY PRIMARY HEADACHE DISORDERS

04/08/2017
Trigemino-Cervical Neuropathic Pain Relieved by Serially Repeated Peripheral Nerve Field Stimulation

09/07/2016
Dr Michael Vagg presents PENS at INS Perth

03/13/2016

Algotec

Monday, July 27, 2015

NeuroStimulator PENS therapy®

HOME PRIVACY POLICY QUALITY POLICY COVID-19 PENS therapy PROBES INDICATIONS PATIENT FAQ's CLINICAL PRESS CONGRESSES CONTACT DISTRIBUTORS

© Algotec Research and Development Reg: 06006919

Registered Address: New Bridge Street House | 30-34 New Bridge Street | London | EC4V 6BJ | United Kingdom